ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Menarini Group and Haisco Pharmaceutical Group side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Menarini GroupHaisco Pharmaceutical Group
studies on the registry81159
open to participants now1453
phase 3 studies under way211
reach primary completion within a year721
programswith a study of their own in two years727

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseMenarini GroupHaisco Pharmaceutical Group
Phase 1

Menarini Group: 4 of its 7 programs at phase 1

  1. Tamsulosinphase 1
  2. KIF18A Inhibitor MEN2501phase 1
  3. Torsemidephase 1
  4. Ibuprofenphase 1
57%

Haisco Pharmaceutical Group: 14 of its 27 programs at phase 1

  1. HSK41959phase 1
  2. HSK46256phase 1
  3. HSK46575phase 1
  4. HSK47977phase 1
  5. HSK55879phase 1

and 9 more — sign in to see them all

52%
Phase 2

Menarini Group: 2 of its 7 programs at phase 2

  1. KAT6 Inhibitor MEN2312phase 2
  2. RPX7009phase 2
29%

Haisco Pharmaceutical Group: 5 of its 27 programs at phase 2

  1. HSK42360phase 2
  2. HSK47388phase 2
  3. HSK55718phase 2
  4. Cetuximabphase 2
  5. HSK50042phase 2
19%
Phase 3

Menarini Group: 1 of its 7 programs at phase 3

  1. elacestrantphase 3
14%

Haisco Pharmaceutical Group: 7 of its 27 programs at phase 3

  1. florensocatibphase 3
  2. HSK44459phase 3
  3. HSK39004phase 3
  4. HSK39297phase 3
  5. anrikefonphase 3

and 2 more — sign in to see them all

26%
Approved, new studies00%

Haisco Pharmaceutical Group: 1 of its 27 programs at approved, new studies

  1. ciprofolapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Menarini Group3 readouts · 0 phase 3

Menarini Group, Nov ’26: 1 program whose next study reaches primary completion

  1. elacestrantphase 3 · Nov 0 · NCT05596409
··········

Menarini Group, Oct ’27: 2 programs whose next study reaches primary completion

  1. RPX7009phase 2 · Oct 0 · NCT06828848
  2. KAT6 Inhibitor MEN2312phase 2 · Oct 24 · NCT06638307
Haisco Pharmaceutical Group9 readouts · 1 phase 3

Haisco Pharmaceutical Group, Nov ’26: 2 programs whose next study reaches primary completion

  1. florensocatibphase 3 · Nov 0 · NCT07915024
  2. HSK55718phase 2 · Nov 0 · NCT07551739

Haisco Pharmaceutical Group, Dec ’26: 3 programs whose next study reaches primary completion

  1. HSK46575phase 1 · Dec 0 · NCT07007910
  2. HSK39297phase 3 · Dec 5 · NCT07616700
  3. HSK47388phase 2 · Dec 20 · NCT07158268
··

Haisco Pharmaceutical Group, Mar ’27: 1 program whose next study reaches primary completion

  1. HSK44459phase 3 · Mar 0 · NCT07623486
··

Haisco Pharmaceutical Group, Jun ’27: 2 programs whose next study reaches primary completion, 1 in phase 3

  1. HSK39004phase 3 · Jun 11 · NCT07658339
  2. cofrogliptinno phase · Jun 30 · NCT07122102
··

Haisco Pharmaceutical Group, Sep ’27: 1 program whose next study reaches primary completion

  1. HSK60002 tabletsphase 1 · Sep 0 · NCT07920809
·
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 21, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Menarini Group

New programs 0

None

Reached a new phase 1

Study stopped 0

None

Primary completion later 1

Haisco Pharmaceutical Group

New programs 1

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

Where they overlap

Conditions where at least two of them have programs: 4 in all. A program counts in each condition its studies name most.

ConditionMenarini GroupHaisco Pharmaceutical Group
Diabetes Mellitus, Type 2both · compare here

Menarini Group in Diabetes Mellitus, Type 2: 1 program

  1. Torsemidephase 1

Their studies: Menarini Group’s studies of Diabetes Mellitus, Type 2 in search

Haisco Pharmaceutical Group in Diabetes Mellitus, Type 2: 4 programs

  1. HSK7653phase 3
  2. Carbon-14phase 1
  3. Ranolazinephase 1
  4. cofrogliptinno phase

Their studies: Haisco Pharmaceutical Group’s studies of Diabetes Mellitus, Type 2 in search

Renal Insufficiencyboth · compare here

Menarini Group in Renal Insufficiency: 1 program

  1. RPX7009phase 2

Their studies: Menarini Group’s studies of Renal Insufficiency in search

Haisco Pharmaceutical Group in Renal Insufficiency: 2 programs

  1. anrikefonphase 3
  2. HSK7653phase 3

Their studies: Haisco Pharmaceutical Group’s studies of Renal Insufficiency in search

Painboth · compare here

Menarini Group in Pain: 1 program

  1. Ibuprofenphase 1

Their studies: Menarini Group’s studies of Pain in search

Haisco Pharmaceutical Group in Pain: 1 program

  1. HSK55718phase 2

Their studies: Haisco Pharmaceutical Group’s studies of Pain in search

Pain, Postoperativeboth · compare here

Menarini Group in Pain, Postoperative: 1 program

  1. Ibuprofenphase 1

Their studies: Menarini Group’s studies of Pain, Postoperative in search

Haisco Pharmaceutical Group in Pain, Postoperative: 1 program

  1. anrikefonphase 3

Their studies: Haisco Pharmaceutical Group’s studies of Pain, Postoperative in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

No gene two of them both target, among the programs whose target is known.

A target, or a pathogen for a vaccine, known for: Menarini Group 6 of 7 · Haisco Pharmaceutical Group 7 of 27 programs (12 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.